50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Labour conference starts with focus on 'immoral' tax cuts
Can Caterpillar Claw Higher in a Falling Market?
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Is Dave & Buster’s Immune to High Inflation and Lower Spending?
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Labour conference starts with focus on 'immoral' tax cuts
Can Caterpillar Claw Higher in a Falling Market?
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Is Dave & Buster’s Immune to High Inflation and Lower Spending?
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Labour conference starts with focus on 'immoral' tax cuts
Can Caterpillar Claw Higher in a Falling Market?
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Is Dave & Buster’s Immune to High Inflation and Lower Spending?
Fire breaks out at world's biggest produce market in Paris
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Germany secures more gas shipments as Scholz visits Gulf
Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Labour conference starts with focus on 'immoral' tax cuts
Can Caterpillar Claw Higher in a Falling Market?
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
Is Dave & Buster’s Immune to High Inflation and Lower Spending?
Fire breaks out at world's biggest produce market in Paris
NASDAQ:LJPC

La Jolla Pharmaceutical - LJPC Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$3.12
$6.22
52-Week Range
N/A
Volume
66,708 shs
Average Volume
158,476 shs
Market Capitalization
$155.11 million
P/E Ratio
51.84
Dividend Yield
N/A
Price Target
N/A
LJPC stock logo

About La Jolla Pharmaceutical (NASDAQ:LJPC) Stock

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.

Receive LJPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

LJPC Stock News Headlines

LJPC Dec 2022 5.000 call(CONTRA
La Jolla Pharmaceutical Co Stock News
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge
3 Biotech Stocks Under $5 to Buy Now
See More Headlines

Receive LJPC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

LJPC Company Calendar

Last Earnings
5/16/2022
Today
9/26/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LJPC
Employees
61
Year Founded
N/A

Profitability

Net Income
$19.66 million
Pretax Margin
8.64%

Debt

Sales & Book Value

Annual Sales
$75.72 million
Book Value
($2.94) per share

Miscellaneous

Free Float
15,885,000
Market Cap
$155.11 million
Optionable
Optionable
Beta
2.39

Key Executives

  • Mr. Larry G. Edwards (Age 50)
    Pres, CEO & Director
    Comp: $858.87k
  • Mr. Michael S. Hearne (Age 59)
    CFO & Sec.
    Comp: $207.38k
  • Ms. Paula Rusu
    VP of Operations
  • Ms. Sandra Vedrick
    Sr. Director of Investor Relations & HR
  • Mr. Luke Seikkula (Age 58)
    Sr. VP of Pharmaceutical Operations
  • Dr. Lakhmir S. Chawla M.D. (Age 51)
    Consultant
  • Mr. Stewart M. Kroll (Age 63)
    Chief Devel. Officer
  • Mr. Mark D. Williams
    Sr. VP of Medical Affairs
  • Mr. Tony N. Hodges FACP
    M.D., Chief Medical Officer













LJPC Stock - Frequently Asked Questions

When is La Jolla Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our LJPC earnings forecast
.

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) posted its quarterly earnings data on Monday, May, 16th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The biopharmaceutical company earned $10.43 million during the quarter, compared to the consensus estimate of $13.10 million. La Jolla Pharmaceutical had a net margin of 8.54% and a negative trailing twelve-month return on equity of 5.46%.

What is George F. Tidmarsh's approval rating as La Jolla Pharmaceutical's CEO?

8 employees have rated La Jolla Pharmaceutical Chief Executive Officer George F. Tidmarsh on Glassdoor.com. George F. Tidmarsh has an approval rating of 49% among the company's employees. This puts George F. Tidmarsh in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of La Jolla Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), Intercept Pharmaceuticals (ICPT), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Advanced Micro Devices (AMD), El Pollo Loco (LOCO), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), NVIDIA (NVDA) and XOMA (XOMA).

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

Who are La Jolla Pharmaceutical's major shareholders?

La Jolla Pharmaceutical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include HealthInvest Partners AB (4.95%), Millennium Management LLC (0.41%), Hollencrest Capital Management (0.31%), Renaissance Technologies LLC (0.23%), O Shaughnessy Asset Management LLC (0.20%) and OLD National Bancorp IN (0.16%). Insiders that own company stock include Darryl Wellinghoff, David A Ramsay and Kevin C Tang.
View institutional ownership trends
.

How much money does La Jolla Pharmaceutical make?

La Jolla Pharmaceutical (NASDAQ:LJPC) has a market capitalization of $0.00 and generates $75.72 million in revenue each year. The biopharmaceutical company earns $19.66 million in net income (profit) each year or $0.12 on an earnings per share basis.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The official website for the company is www.lajollapharmaceutical.com. The biopharmaceutical company can be reached via phone at (617) 715-3600, via email at info@ljpc.com, or via fax at 858-626-2851.

This page (NASDAQ:LJPC) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.